Accuray Incorp Stock Price, News & Analysis

Accuray Incorporated (NASDAQ: ARAY) has announced the granting of equity inducement awards to Dr. Jean-Philippe Pignol, its new Chief Medical & Technology Officer. As part of his induction, Dr. Pignol received 53,191 restricted stock units and a stock option for 96,480 shares, effective April 30, 2021. The stock option has a ten-year term with an exercise price of $4.70. Vesting of the awards will occur annually and monthly, contingent upon Dr. Pignol's continued service. These inducement awards comply with NASDAQ Listing Rule 5635(c)(4) and are consistent with the 2016 Equity Incentive Plan.

Geisinger has become the first hospital system in the U.S. to implement Accuray's Synchrony technology on its CyberKnife® S7™ and Radixact® Systems for advanced cancer care. This initiative aims to enhance the targeting of radiation therapy while minimizing damage to healthy tissue. Synchrony utilizes AI for real-time radiation adjustments based on tumor movement, leading to more efficient treatment. Geisinger's investment is part of their expansion at the Henry Cancer Center, where hypofractionated radiotherapy is now possible, offering higher doses with greater precision.

Accuray announced that its customers secured the top two spots in the MArkerless Lung Target Tracking CHallenge (MATCH) using the Synchrony technology on the Radixact and CyberKnife systems. The challenge evaluated the accuracy of tumor-tracking algorithms, with scoring based on radiation therapy system precision. Accuray's technology allows real-time adaptation of treatment based on patient movement, improving treatment accuracy and patient comfort. The results demonstrate Synchrony's potential to enhance lung cancer therapy, offering a non-invasive option for medically inoperable patients.

Accuray Incorporated (NASDAQ: ARAY) reported Q3 fiscal 2021 results, with net revenue of $102.6 million, up from $99.5 million year-over-year. System revenue in China amounted to $24.9 million, while gross orders were $87.4 million, a 16% increase from Q2. However, net loss stood at $0.4 million, a substantial decline from a net income of $2.6 million in the same quarter last year. The company also received regulatory approval for its ClearRT™ Helical kVCT Imaging in Japan. Cash reserves increased to $130.1 million.

Accuray Incorporated (NASDAQ: ARAY) has announced that its ClearRT helical fan-beam kVCT imaging system has been in clinical use for over two months, demonstrating significant potential in radiation oncology. The first patient treatments at Willis-Knighton Cancer Center show enhanced imaging quality, allowing for superior tumor visualization and treatment precision. ClearRT has received Shonin approval in Japan and FDA 510(k) clearance, with a CE Mark expected by the end of June 2021, expanding its market accessibility. The first commercial ClearRT systems have been shipped as scheduled.

Accuray Incorporated (NASDAQ: ARAY) will release its third-quarter financial results for fiscal year 2021, ending March 31, 2021, on April 27, 2021, post-market. The management will hold a conference call at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results. Dial-in numbers are provided for participants, and a live webcast will be available through the company's Investor Relations website. Accuray focuses on innovative radiation therapy solutions aimed at enhancing patient care.

Accuray Incorporated (NASDAQ: ARAY) will participate in the Cowen Annual Health Care Conference on March 2, 2021, at 11:50 AM Pacific. The event is an invitation-only conference connecting over 325 health care companies with institutional investors, focusing on investment opportunities and sector trends. A live webcast of the Fireside Chat will be available on Accuray's website. Accuray is dedicated to innovating radiation therapy solutions to improve patient outcomes across oncology and neuro-radiosurgery.

Accuray Incorporated (NASDAQ: ARAY) has appointed Byron C. Scott, M.D., MBA, to its Board of Directors as of February 12, 2021. Dr. Scott is a renowned physician executive with extensive experience in healthcare analytics and technology. Currently, he teaches at the University of Massachusetts and Jefferson University. His previous roles include Deputy Chief Health Officer at IBM Watson Health and leadership positions at Truven Health Analytics and EmCare. The appointment aims to strengthen Accuray's management team amid evolving radiation therapy market demands.

Accuray Incorporated (NASDAQ: ARAY) will participate in BTIG's Virtual MedTech Conference on February 18 at 12:30 PM Pacific time. The management team will engage in a Fireside Chat, which can be accessed live via the Accuray website. This event aims to connect more than 100 corporate management teams with institutional investors to discuss investment opportunities and sector trends in the healthcare space. Accuray is dedicated to improving lives through advanced radiation therapy solutions.